Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Resusix is a portable, shelf-stable blood product derived from pooled human plasma that has undergone solvent/detergent (S/D) pathogen inactivation and spray drying. It is designed as a resuscitation fluid for use in trauma patients experiencing severe blood loss, particularly in remote or austere environments where traditional fresh frozen plasma (FFP) is impractical due to cold chain requirements. The product maintains functional clotting capability and aims to promote systemic vascular stability while preventing coagulopathy and inflammation. Resusix offers an extended shelf life of over two years and can be rehydrated for infusion when needed. It provides a safer alternative to FFP by being free of micro particles and cell fragments commonly found in FFP[1][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on resusix.